The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets, multi-target agonists, and next-generation injectables is reshaping the competitive landscape at pace, with fresh regulatory approvals, pivotal Phase 3 data, and an expanding list of indications that stretches far beyond weight loss and type 2 diabetes.
This guide covers every major GLP-1 drug pipeline candidate worth watching in 2026: the compounds already approved, the assets awaiting regulatory decisions, and the emerging molecules that could define the next decade of metabolic medicine.
New Approvals Already Reshaping the Market
Two significant regulatory decisions in early 2026 have shifted the competitive dynamics of the GLP-1 drug pipeline before the year reached its midpoint.
On 19 March 2026, the FDA approved a higher-dose formulation of semaglutide, Wegovy HD, at 7.2 mg for once-weekly subcutaneous administration. The approval was granted under the FDA’s Commissioner’s National Priority Voucher pilot programme, which expedites review for priority therapies. In the STEP UP clinical trial, the 7.2 mg dose produced a mean weight loss of 20.7% at 72 weeks, compared with 17.5% at the previously approved 2.4 mg dose and 2.4% with placebo. The approval extends the existing Wegovy franchise while raising the efficacy ceiling for injectable semaglutide.
Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lilly’s brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management. Unlike oral semaglutide, which must be taken fasting with limited water, orforglipron can be taken at any time of day without food or water restrictions. This distinction is clinically and commercially significant. David Ricks, Chair and Chief Executive Officer of Eli Lilly, noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, citing access barriers, stigma, and the complexity of existing treatment options. Lilly has submitted orforglipron for approval in more than 40 countries, with launches expected in each market following regulatory clearance.
CagriSema: Awaiting a Critical FDA Decision
Novo Nordisk’s CagriSema represents one of the most consequential pending decisions across the GLP-1 drug pipeline in 2026. The fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg pairs a GLP-1 receptor agonist with a long-acting analogue of amylin, a pancreatic hormone that reduces appetite and slows gastric emptying. The combination is designed to produce additive weight loss beyond what either molecule achieves independently.
Novo Nordisk filed its New Drug Application with the FDA on 18 December 2025, based on data from the REDEFINE 1 trial. That study enrolled 3,417 adults with obesity or overweight and without type 2 diabetes, and showed a mean weight loss of 22.7% at 68 weeks in patients who remained on treatment. Under standard FDA review timelines, a decision is expected in late 2026.
As covered in an earlier analysis of CagriSema’s Phase 3 data, the journey to that decision has not been without complexity. In February 2026, full results from the REDEFINE 2 study showed CagriSema achieving 23% weight loss at 84 weeks but falling short of its primary endpoint under the treatment policy estimand (which measures efficacy across all patients regardless of whether they completed treatment, rather than only those who remained on it). Separately, in the REDEFINE 4 head-to-head trial against tirzepatide, CagriSema produced approximately 20.2% body weight reduction at 84 weeks, compared with 23.6% for tirzepatide.
Despite this, Novo Nordisk remains committed to CagriSema as the potential first approved GLP-1 and amylin combination product. The company is exploring higher-dose formulations and has signalled plans to investigate the full weight-loss potential of the combination in further studies.
Retatrutide: Surgery-Level Results from a Triple Agonist
The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lilly’s investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.
On 21 May 2026, Lilly announced positive topline results from TRIUMPH-1 (not yet peer-reviewed), the pivotal Phase 3 obesity trial. Across 2,339 adults with obesity or overweight, all three doses of retatrutide met the primary and key secondary endpoints at 80 weeks. On the highest 12 mg dose, participants lost an average of 28.3% of their body weight, equivalent to approximately 70.3 pounds. In a pre-specified extension cohort restricted to participants with a BMI of at least 35, average weight loss reached 30.3% at 104 weeks.
“Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease,” said Ania Jastreboff, MD, PhD, Lead Investigator and Director of the Yale Obesity Research Center.
Dan Skovronsky, Lilly’s Chief Scientific and Product Officer, described the results as extraordinary. “We haven’t seen that level of weight loss before with these kinds of medicines,” he said. The 30% figure had, until now, been the exclusive territory of bariatric surgery rather than pharmacotherapy.
Safety findings were consistent with the incretin drug class. Nausea was reported in 42.4% of patients on the 12 mg dose, with diarrhoea and constipation affecting 32% and 26.1% respectively. Dysaesthesia, an abnormal sensory condition, occurred in more than 12% of patients at the highest dose, consistent with earlier retatrutide studies.
In March 2026, Lilly also reported positive Phase 3 data for retatrutide in type 2 diabetes. The TRANSCEND-T2D-1 trial demonstrated A1C reductions of up to 2.0% and weight loss of up to 16.8% at 40 weeks, with no plateau observed through the end of the treatment period. The overall TRIUMPH Phase 3 programme covers obesity, obstructive sleep apnoea, and knee osteoarthritis, and has enrolled more than 5,800 participants globally.
The Oral GLP-1 Race: Aleniglipron and Beyond
The approval of Foundayo has confirmed the commercial viability of the oral small-molecule GLP-1 category, and competition is intensifying. Structure Therapeutics is among the most advanced challengers, with its oral GLP-1 receptor agonist aleniglipron generating Phase 2 data that has drawn significant industry attention.
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point. The FDA provided positive end-of-Phase 2 feedback, and Phase 3 initiation is on track for the third quarter of 2026. Structure raised $748 million in financing in 2025 to fund the aleniglipron programme and its broader oral metabolic portfolio.
The oral GLP-1 space is also drawing significant strategic investment from larger players. In early 2026, Roche paid $100 million to secure a non-exclusive patent licence from Structure’s subsidiary Gasherbrum Bio, covering intellectual property relevant to CT-996, the oral GLP-1 compound Roche acquired through its $2.7 billion buyout of Carmot Therapeutics in late 2023. The deal reflects the growing commercial and legal complexity of the oral small-molecule space as companies move to protect pipeline assets ahead of potential future infringement claims.
Beyond aleniglipron, Structure is also advancing two oral small-molecule amylin receptor agonists, ACCG-2671 and ACCG-3535, with potential as standalone treatments or as fixed-dose oral combinations.
Expanding Indications: Beyond Obesity and Diabetes
The GLP-1 drug pipeline in 2026 reaches well beyond weight management and glycaemic control. Regulatory decisions and large-scale clinical evidence are establishing the drug class as a multi-system therapeutic platform.
In liver disease, semaglutide received FDA accelerated approval in August 2025 for metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced fibrosis. The 2026 American Diabetes Association Standards of Care now list GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and biopsy-proven MASH or elevated fibrosis risk. In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population.
Tirzepatide continues to broaden its label. Eli Lilly is awaiting an FDA decision on a new indication for Mounjaro covering the reduction of major adverse cardiovascular events in patients with type 2 diabetes, supported by the SURPASS CVOT trial. In December 2025, the FDA also expanded the Mounjaro indication to include paediatric patients aged ten and over with type 2 diabetes, following results from the SURPASS-PEDS trial.
The one high-profile setback has come from neurology. Phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimer’s disease did not meet their primary endpoints, tempering the earlier hypothesis that GLP-1s might offer direct neuroprotective benefits. Research continues, but immediate approval in this indication now appears unlikely.
The Scale of the Pipeline
The breadth of development activity reflects the commercial and clinical ambitions of a drug class that has arguably become the most consequential in modern medicine. According to IQVIA, more than 193 obesity pipeline assets were in active development as of October 2025, up from 181 just five months earlier. The pipeline spans single receptor agonists, dual agonists incorporating GIP, glucagon, or amylin targets, triple agonists, and next-generation oral formulations. Conditions under active investigation include prediabetes, heart failure with preserved ejection fraction, obstructive sleep apnoea, knee osteoarthritis, polycystic ovarian syndrome, and inflammatory bowel disease.
Market analysts anticipate eight or more novel GLP-1-based approvals for chronic weight management over the next four years, as the drug class extends from its metabolic origins into a broader platform for addressing diseases with underlying inflammatory and cardiometabolic components. For the GLP-1 drug pipeline, 2026 is not a consolidation year. It is an acceleration.
